Saxenda (liraglutide 3.0 mg) is titrated over five weeks, starting at 0.6 mg per day and increasing by 0.6 mg each week until reaching the full maintenance dose. The schedule is designed to minimize gastrointestinal side effects, particularly nausea, which is the most common reason people struggle with the medication early on. The process is straightforward on paper, but real-world titration involves judgment calls about pacing, tolerability, and what to do when your body pushes back.
The Week-by-Week Schedule
The dose escalation moves in five equal steps, each lasting one week:
- Week 1: 0.6 mg once daily
- Week 2: 1.2 mg once daily
- Week 3: 1.8 mg once daily
- Week 4: 2.4 mg once daily
- Week 5 onward: 3.0 mg once daily (maintenance dose)
Each injection is subcutaneous and given at roughly the same time every day, in the abdomen, thigh, or upper arm. The pen is pre-filled and pre-mixed, so no reconstitution is needed. If you cannot tolerate a dose increase, the standard approach is to delay the next step by an additional week rather than pushing through. For adolescents aged 12 and older, the same schedule applies, though stepping back down to a previously tolerated dose is also an option if side effects persist.
Why Gradual Escalation Exists
Liraglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone involved in slowing stomach emptying, suppressing appetite, and signaling fullness to the brain. When the body first encounters the drug, the abrupt change in how fast your stomach empties food tends to produce nausea, and sometimes vomiting or diarrhea. Titration gives your gastrointestinal system time to adapt before each dose bump.
From a pharmacokinetic standpoint, liraglutide reaches steady-state blood levels after about three days of consistent dosing at a given dose level.1PubMed Central. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics The one-week intervals at each step give more than enough time for blood concentrations to stabilize and for your gut to begin adjusting before the next increase. Jumping straight to 3.0 mg would produce much more intense nausea and would likely push more people to quit entirely. Slow dose titration, dietary adjustments, and sometimes supportive medications are the standard approach to keeping people on treatment.2PubMed Central. Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Managing Side Effects During the Climb
Nausea gets the most attention, but you may also experience diarrhea or constipation, headache, fatigue, abdominal bloating, or decreased appetite (which is partly the intended effect). For most people, nausea peaks during the first two to three weeks and then fades as the body adjusts to each dose level.
A few practical strategies help. Eat smaller, more frequent meals rather than large ones, because a stomach that is emptying slowly handles small volumes much more comfortably. Avoid high-fat and very rich foods during escalation weeks, as these tend to amplify nausea. Stay well hydrated. Some clinicians suggest taking the injection in the evening so that the worst of the queasiness happens overnight.
If a particular dose step is hard to tolerate, you can hold at that dose for an extra week before moving up. This is explicitly built into the prescribing guidance and does not mean the medication is failing. What you should not do is skip a dose level or jump ahead. The entire point of titration is letting your system adjust in a controlled sequence.
In a real-world study of patients taking liraglutide 3.0 mg while awaiting bariatric surgery, only about 10% discontinued the medication because of tolerability problems.3Obesity Surgery. Liraglutide 3.0 mg (Saxenda) for Weight Loss and Remission of Pre-Diabetes That means the large majority of people get through escalation, even if some weeks feel uncomfortable.
What Happens If You Pause or Miss Doses
If you miss a single day, take the next scheduled dose at your usual time. Do not double up. A one-day gap is not enough to lose your adaptation to the drug.
If you have been off Saxenda for more than 14 days, the standard guidance is to restart the full titration from 0.6 mg. The reason mirrors the original rationale: your body loses its adaptation to liraglutide’s effect on gastric emptying. Going straight back to 3.0 mg after a two-week gap can produce the same intense nausea you would experience if you had never taken it at all. The re-titration takes the same five weeks, which is frustrating but necessary.
This matters for planning. If you have upcoming surgery, extended travel, or any situation where you may not have access to your medication for a stretch, try to avoid gaps longer than two weeks. Running out of pens and waiting on a refill is one of the most common reasons people end up re-titrating, and each restart delays your time at the effective maintenance dose.
Can You Stay Below 3.0 mg
The official prescribing information says the maintenance dose is 3.0 mg, and that if you cannot tolerate it, you should discontinue Saxenda rather than maintain a lower dose. The clinical trials that supported the drug’s approval were designed around the 3.0 mg target, so that is where the strongest evidence sits.
In practice, the story is more nuanced. The SCALE Diabetes trial tested 1.8 mg alongside 3.0 mg and placebo. Patients on 1.8 mg lost about 4.7% of their body weight over 56 weeks, compared to 6.0% with 3.0 mg and 2.0% with placebo.4JAMA. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial The gap between 1.8 mg and 3.0 mg was relatively small, and both doses clearly outperformed placebo. That finding suggests a sub-maximal dose still delivers a real benefit for some people, even if it is not the labeled recommendation.
Some clinicians take a pragmatic approach: if a patient is losing weight and tolerating 2.4 mg well but struggling with nausea at 3.0 mg, staying at the tolerated dose may produce better long-term results than abandoning the drug altogether. If you are in this situation, it is a conversation worth having with your prescriber rather than assuming the label’s all-or-nothing framing is the only option.
Medications That May Need Adjustment
Because GLP-1 receptor agonists slow gastric emptying, they can theoretically change how fast other oral medications are absorbed. For most drugs, this effect turns out to be clinically insignificant.5Drug Design, Development and Therapy. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist Your body still absorbs the medication; peak blood levels may just arrive a bit later.
There are exceptions worth knowing about. Studies of related GLP-1 drugs have found significant changes in exposure for oral contraceptives (with tirzepatide) and for levothyroxine (with oral semaglutide).6Drug Design, Development and Therapy. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist While those findings involve different GLP-1 drugs rather than liraglutide specifically, the underlying mechanism is shared, and the interaction is worth monitoring. If you take thyroid medication or hormonal birth control, tell your prescriber before starting Saxenda so they can check levels or adjust timing if needed.
For people with type 2 diabetes who are on insulin or sulfonylureas, adding Saxenda increases the risk of low blood sugar. Doses of those diabetes medications often need to be reduced during or shortly after titration. Your prescriber should plan for this proactively rather than waiting for a hypoglycemic episode.
What Weight Loss to Expect After Completing Titration
The titration phase itself is not where most of the weight loss happens. You spend the first four weeks on sub-therapeutic doses, and the appetite-suppressing effects build as the dose climbs. Meaningful results typically emerge over months at the full 3.0 mg dose.
The largest trial, involving over 3,700 adults without diabetes, found that people on liraglutide 3.0 mg lost an average of about 8.4 kg over 56 weeks, compared to about 2.8 kg with placebo. Roughly 63% of the liraglutide group lost at least 5% of their starting weight, and about a third lost more than 10%.7PubMed. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
For people with type 2 diabetes, the numbers tend to be somewhat lower, with the 3.0 mg group averaging about 6% body weight loss over 56 weeks.8JAMA. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial A trial in people with obesity and moderate-to-severe obstructive sleep apnea showed about 5.7% weight loss at 32 weeks, along with a significant reduction in the number of breathing interruptions per hour during sleep.9International Journal of Obesity. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
These are averages, so individual results vary widely. Early response during the first 12 to 16 weeks at full dose is often used as a practical gauge: if you have not lost at least 5% of your body weight by that point, your prescriber will likely discuss whether continuing makes sense or whether switching to a different medication is a better path.
A real-world study of patients awaiting bariatric surgery found average weight loss of about 11 kg at 26 weeks and 14 kg at 52 weeks, with about 86% of patients achieving the 5% threshold and a third reaching 10% or more at one year.10Obesity Surgery. Liraglutide 3.0 mg (Saxenda) for Weight Loss and Remission of Pre-Diabetes That study included patients who were highly motivated (they were working toward surgical eligibility), so the results may be on the optimistic end, but they illustrate what is achievable when adherence is strong.
How Saxenda Titration Compares to Weekly GLP-1 Injections
If you have heard about semaglutide (Wegovy) or tirzepatide (Zepbound), you might wonder how Saxenda’s daily titration stacks up against those weekly alternatives. The basic principle is identical: start low, go slow, and let the gut adjust. Weekly injectables spread their dose escalation over longer intervals, typically four weeks per step, partly because the drug itself has a much longer half-life and takes longer to reach steady state at each level.
Liraglutide’s half-life is about 13 hours, which means blood levels rise and fall noticeably within each 24-hour cycle and stabilize quickly when you start a new dose. Steady state arrives in roughly three days.11PubMed Central. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics That faster stabilization is why the steps can be just one week apart rather than four. The trade-off is daily injections for the life of the treatment, which some people find burdensome compared to a weekly shot.
Weight loss outcomes also differ between the medications, with semaglutide 2.4 mg generally producing greater average weight loss than liraglutide 3.0 mg. But insurance coverage, drug availability, cost, and individual tolerability all shape which medication ends up being the right fit. The titration process itself, regardless of the specific drug, serves the same purpose: getting you to an effective dose with the fewest side effects along the way. If you have already been through Saxenda’s titration and are considering switching to a weekly injectable, the good news is that you have already demonstrated your body can adapt to GLP-1 agonism, which tends to make the next titration smoother even though the specific drug and schedule differ.
Titration Considerations for Adolescents
Saxenda is approved for weight management in adolescents aged 12 and older, and the five-step titration schedule is the same as for adults. In practice, two things tend to differ. First, clinicians are generally quicker to step a teenager back down to a previously tolerated dose rather than holding at a tough dose for an extra week. The reasoning is partly about compliance: a 14-year-old who spends a week feeling persistently nauseated is more likely to refuse the next injection altogether than an adult who can rationalize through the discomfort.
Second, the appetite changes during titration can feel psychologically disorienting for younger patients. An adult who has dieted before usually has a frame of reference for what reduced hunger feels like. A teenager experiencing a sharp drop in appetite for the first time may find it alarming or confusing, and in some cases it can blur the line between therapeutic appetite reduction and disordered eating patterns. Parents and prescribers typically maintain closer contact during the escalation weeks, checking in not just on physical side effects but on the adolescent’s relationship with food and body image. None of this changes the titration schedule on paper, but it does change how closely the process is monitored and how readily dose adjustments are made.